Network-Based HDAC6 Activity Assessment Predicts Responses to the HDAC6 Inhibitor Ricolinostat in Patients With Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer
Nat Cancer 2022 Dec 30;[EPub Ahead of Print], TZ Zeleke, Q Pan, C Chiuzan, M Onishi, Y Li, H Tan, MJ Alvarez, E Honan, M Yang, PL Chia, P Mukhopadhyay, S Kelly, R Wu, K Fenn, MS Trivedi, M Accordino, KD Crew, DL Hershman, M Maurer, S Jones, A High, J Peng, A Califano, K Kalinsky, J Yu, J SilvaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.